WO2011083391A3 - Biomarqueurs pour une thérapie du cancer par un anti-igf-1r - Google Patents

Biomarqueurs pour une thérapie du cancer par un anti-igf-1r Download PDF

Info

Publication number
WO2011083391A3
WO2011083391A3 PCT/IB2010/056071 IB2010056071W WO2011083391A3 WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3 IB 2010056071 W IB2010056071 W IB 2010056071W WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
biomarkers
cancer therapy
therapy
cancer
Prior art date
Application number
PCT/IB2010/056071
Other languages
English (en)
Other versions
WO2011083391A2 (fr
Inventor
Stephanie Janet Green
Antonio Gualberto
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2011083391A2 publication Critical patent/WO2011083391A2/fr
Publication of WO2011083391A3 publication Critical patent/WO2011083391A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur l'utilisation d'IGF-1 libre, et du rapport insuline/IGFBP dans le sang, en tant que biomarqueurs pour une thérapie du cancer par un antagoniste de l'IGF-1R, ainsi que sur un procédé pour le traitement du cancer par une thérapie du cancer utilisant l'IGF-1 R chez des patients choisis sur la base de ces biomarqueurs.
PCT/IB2010/056071 2010-01-05 2010-12-24 Biomarqueurs pour une thérapie du cancer par un anti-igf-1r WO2011083391A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29247110P 2010-01-05 2010-01-05
US61/292,471 2010-01-05

Publications (2)

Publication Number Publication Date
WO2011083391A2 WO2011083391A2 (fr) 2011-07-14
WO2011083391A3 true WO2011083391A3 (fr) 2011-09-01

Family

ID=43920382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/056071 WO2011083391A2 (fr) 2010-01-05 2010-12-24 Biomarqueurs pour une thérapie du cancer par un anti-igf-1r

Country Status (2)

Country Link
JP (1) JP2011141279A (fr)
WO (1) WO2011083391A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
WO2023276869A1 (fr) * 2021-06-28 2023-01-05 学校法人 久留米大学 Procédé de prédiction d'un pronostic après traitement avec un inhibiteur d'angiogenèse, et multithérapie anticancéreuse

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (fr) * 2001-01-05 2002-07-11 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (fr) * 2006-06-02 2007-12-13 Pfizer Products Inc. Analyse de cellules tumorales circulantes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037777A1 (fr) 1995-05-23 1996-11-28 Nelson Randall W Immuno-dosage spectrometrique de masse
BR0116575A (pt) 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2427964T3 (es) 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2484000A1 (fr) 2002-05-24 2003-12-04 Schering Corporation Anticorps anti-igfr humain neutralisant
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
SE0203746D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
CA2519113C (fr) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
EP2365001A3 (fr) 2003-05-01 2012-03-28 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
RU2379308C2 (ru) 2004-04-02 2010-01-20 Оси Фармасьютикалз, Инк. 6, 6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
EP1827487A2 (fr) 2004-11-17 2007-09-05 Board of Regents, The University of Texas System Immunotherapie de cancer impliquant p53
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
AU2007245164A1 (en) 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
KR101443400B1 (ko) 2006-07-07 2014-10-02 브리스톨-마이어스 스큅 컴퍼니 피롤로트리아진 키나제 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (fr) * 2001-01-05 2002-07-11 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (fr) * 2006-06-02 2007-12-13 Pfizer Products Inc. Analyse de cellules tumorales circulantes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUALBERTO A. ET AL.: "1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition", EUR. J. CANCER SUPPLEMENTS, vol. 7, no. 2, September 2009 (2009-09-01), pages 88 - 89, XP026560258 *
GUALBERTO A. ET AL.: "Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions", ONCOGENE, vol. 28, no. 34, 27 August 2009 (2009-08-27), pages 3009 - 3021, XP002636347 *
GUALBERTO A. ET AL.: "Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab", BRIT. J. CANCER, vol. 104, no. 1, 4 January 2011 (2011-01-04), pages 68 - 74, XP002636348 *
KARP D.D. ET AL.: "Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer", J. CLIN. ONCOL., vol. 27, no. 15, 20 May 2009 (2009-05-20), pages 2516 - 2522, XP002636346 *
KARP D.D. ET AL.: "Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin", J. THORAC. ONCOL., vol. 4, no. 11, November 2009 (2009-11-01), pages 1397 - 1403, XP002636345 *

Also Published As

Publication number Publication date
JP2011141279A (ja) 2011-07-21
WO2011083391A2 (fr) 2011-07-14

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
GB201020860D0 (en) Disulfiram formulation and uses thereof
WO2013186240A3 (fr) Analogue peptidique d'exendine-4
WO2011112953A3 (fr) Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs et de type basal
WO2012139093A3 (fr) Modulateurs sélectifs des récepteurs des androgènes pour le traitement du diabète
EP2692366A4 (fr) Instrument médical pourvu d'une couche de revêtement coulissante, et seringue
MX2012004286A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
EP3052131A4 (fr) Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
WO2010083385A3 (fr) Composés permettant de réduire la résistance aux médicaments et leurs utilisations
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
PH12015501088A1 (en) Dimeric compounds
EP3061452A4 (fr) Utilisation d'icariine pour préparer un médicament destiné à prévenir ou à traiter une baisse des cellules sanguines
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
EP3016607A4 (fr) Systèmes et procédés pour l'irradiation in vivo de sang
WO2015001013A3 (fr) Anticorps anti-ifn-alpha humains
IL207722A (en) Pyridopyrazinone Derivatives as Insulators, Methods of Preparation and Use for Diabetes
GB201223025D0 (en) Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
WO2012082821A3 (fr) Traitements de mélanomes
WO2011163512A3 (fr) Traitement anticancéreux
WO2011083391A3 (fr) Biomarqueurs pour une thérapie du cancer par un anti-igf-1r

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A2